Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 2 Surgical sample PDX by clinical molecular subtype

From: Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study

Clinical molecular subtype Total implanted Any tumor growth Verified breast tumor (%)
ER-/HER2+ 3 1 1 (33.3)
ER+/HER2+ 5 0 0 (0.0)
LumA 3 0 0 (0.0)
LumB 18 2 0 (0.0)
LumUnk 1 0 0 (0.0)
Triple negative 9 4b 5 (55.6)
Totals 35a 7 6 (17.1)
  1. Abbreviations: PDX patient-derived xenograft, ER estrogen receptor, HER2 human epidermal growth factor receptor 2, LumA luminal A, LumB luminal B, LumUnk luminal unknown
  2. aAn additional two tumors were implanted and had growth but were not available for pathological confirmation
  3. bOne triple negative PDX did not grow to the defined growth threshold due to mouse health condition, but did passage with verification